Exploring a new treatment approach for rheumatoid arthritis through protein signaling.
Official title: Modulation of Protein S-nitrosylation Signaling as a Potential Therapeutic Breakthrough in Rheumatoid Arthritis
Funded at Gsno Therapeutics, INC. · NIH-10817318 · Data updated 2026-11-12
This study is exploring a new way to help people with rheumatoid arthritis by using a treatment that targets a specific enzyme to reduce inflammation and protect your joints, and we’ll be looking to see if it helps improve your symptoms and joint health.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gsno Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Shelton, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $279,654 |
| NIH project number | 1R43AR083703-01 |
| Project ID | NIH-10817318 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who are experiencing significant inflammation and joint damage.
✕Less likely to help
Patients with rheumatoid arthritis who are not responsive to new therapeutic approaches or those with contraindications to the study drug may not benefit from this research.
What this research studies
This research investigates a novel therapeutic strategy for rheumatoid arthritis (RA) by targeting protein S-nitrosylation signaling. The approach involves inhibiting an enzyme called GSNOR, which is linked to oxidative stress and inflammation in RA. By increasing levels of a protective molecule, GSNO, the research aims to restore healthy signaling pathways that can reduce inflammation and protect joint tissues. Patients may be monitored for improvements in symptoms and joint health as part of this innovative treatment approach.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly alleviates symptoms and slows the progression of rheumatoid arthritis.
How similar studies have gone: While the specific approach of targeting GSNOR for RA is novel, similar strategies targeting oxidative stress and inflammation have shown promise in other autoimmune conditions.
Where this research is happening
-
Gsno Therapeutics, INC.
Shelton, United States Active
Researchers
- Principal investigator: Bradley, Matthews Ogden — Gsno Therapeutics, INC.
- Study coordinator: Bradley, Matthews Ogden
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Role of Stabilin receptors in rheumatoid arthritis
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Pregnancy changes in rheumatoid arthritis and new treatment ideas
This research seeks to understand why some women’s rheumatoid arthritis improves during pregnancy and how to predict and mimic that effect to make treatments safer and more effective for pregnant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.